Vitiligo is a chronic skin condition characterized by the loss of melanocytes, leading to the appearance of white patches on the skin. One of the critical phases in managing vitiligo is identifying its stable phase, which is essential for effective treatment and monitoring.
Defining the Stable Phase
The stable phase of vitiligo is identified when the white patches on the skin have not expanded or increased in number over a period of six months. During this phase, the edges of the patches are sharp and distinct from the surrounding normal skin. Additionally, there is no evidence of new patches appearing. This phase is also marked by the absence of the Koebner phenomenon, where skin injuries lead to new patches.
Clinical Characteristics
In the stable phase, the patches have a clear boundary with the surrounding skin, and the depigmented areas remain unchanged. Under Wood’s lamp examination, the depigmented areas show uniform fluorescence without any surrounding pigment reduction zones. Some patients may experience minor repigmentation around hair follicles, but overall, the repigmentation process is slow.
Duration and Variability
The stable phase typically lasts for more than six months, although this can vary from person to person. About 30% of patients may remain in the stable phase for an extended period, while others might shift back to the progressive phase due to factors such as pregnancy, injury, or stress. Regular monitoring through photographic comparisons every three months is recommended.
Pathological Mechanisms
During the stable phase, the autoimmune attack on melanocytes is reduced, leading to lower levels of anti-melanocyte antibodies in the blood. There is also a decrease in CD8+ T-cell infiltration in the affected areas, and the Th1/Th2 cytokine network becomes more balanced. However, the remaining melanocytes still exhibit functional inhibition.
Treatment Strategies
The stable phase offers a more favorable environment for treatment. Narrowband UVB phototherapy or 308nm excimer laser combined with topical calcineurin inhibitors are preferred. For acral types, autologous melanocyte transplantation can be considered, while segmental types may benefit from mini-graft transplantation. The use of potent corticosteroids should be avoided to prevent skin atrophy.
Prognosis and Recommendations
The repigmentation rate for facial and neck lesions can reach up to 70%, while it is only around 30% for joint areas. Children generally have a better repigmentation capacity than adults. Patients who have been in the stable phase for over two years have a lower risk of relapse, but sun protection is still necessary to prevent the fading of pigmented islands.
Patients in the stable phase should maintain a balanced diet, moderately consume copper-rich foods such as nuts and animal liver, and avoid excessive intake of vitamin C. Daily use of SPF30+ sunscreen is recommended to protect the depigmented areas, and wearing cotton clothing can reduce skin friction. Engaging in 30 minutes of aerobic exercise three times a week can help regulate immune function, and gentle exercises like Tai Chi can alleviate psychological stress. It is also suggested to have thyroid function and autoantibody tests every six months to detect any associated autoimmune diseases early.
Conclusion
Understanding the stable phase of vitiligo is crucial for both patients and healthcare providers. It allows for more effective treatment planning and helps in managing the condition more efficiently. Regular monitoring and adherence to treatment guidelines are essential for achieving the best possible outcomes.
Related topics:
